Lp(a) lipoprotein is a genetically regulated trait, and its concentration in serum seems to be independent from that of other lipoprotein classes (1, 2). The physiological function of Lp(a) has not been clarified in detail, although epidemiological studies show it to be an independent risk factor for the development of ischemic heart disease (3,4). 1'his atherogenicity seems to be deduced by its binding ffmity to glycosaniinoglycans and to the tight structural imilarity of the apoprotein(a) moiety to plasminogen (5,6). (8) reported that decreased albumin concentration and oncotic pressure might be related to the enhanced hepatic synthesis of lipoproteins containing apoprotein B-100, and several authors have speculated about the loss of high-density lipoprotein in the urine, which might lead to a secondary increase in circulating triglycerides, owing to decreased physiological lipoprotein activator apoprotein C II in plasma (9, 10).
The possible role of kidney in the regulation or modulation of Lp(a) metabolism was first suggested by Parra eta!. (11) , who found an enhanced serum Lp(a) concentration in chronically hemodialyzed patients. Prompted by their finding, we investigated patients with massive proteinuria and with nephropathy of different origin. We found a significantly increased concentrationof Lp(a) in the serum of these patients, independent of their serum cholesterol and triglyceride concentrations as compared with controls. Our data indicate a possible regulatory function of kidney in Lp(a) metabolism.
PatIents and Methods

We investigated 37 patients [mean age, 41.2 (SD 14.7)
years] suffering from chronic renal disease of different histological origin: 24 men, age 46.8 (SD 10.6) years, and 13 women, age 41.2 (SD 14.7) years. There is no evidence for sex-related differences in the Lp(a) concentration in serum. Therefore we did not evaluate our patients according to sex (12). Table 1 lists patients, grouped by histological results obtained from their renal needle biopsies, and their serum Lp(a) concentrations.
After an overnight fast and having given informed consent, each patient had venous blood sampled. The blood was allowed to clot and centrifuged (room temperature, 20 mm, 1400 x g). We added 15 mmol/L NaN3 to the serum, then stored it at 20#{176}C for later investigation. We quantified serum cholesterol and triglyceride concentrations enzymatically, using conventional , F.R.G.) . The concentration of Lp(a) in serum was determined by Laurell electrophoresis (13). In addition to lipid variables we measured daily urinary protein loss, serum creatinine, IgG, and transferrin, and calculated the IgG clearance/transferrin clearance ratio as a "selectivity index" (14). Table 2 shows lipid values for our patients compared with those for age-and sex-matched controls. From epidemiological data it is known that Lp(a) >300 mg/L is a strong independent risk factor for ischemic heart disease (4). We found a significantly increased Lp(a) concentration in our patient group; the number of patients with Lp(a) >300 mg/L was fourfold that for the controls. We found no correlation between Lp(a) concentration and urinary protein loss, selectivity index, or endogenous creatinine clearance in the total group of patients. In contrast, in the seven patients with minimal change disease (MCD) there was a Table 3 ).
Results
Interestingly, in two of the three patients with primary amyloidosis we found extremely high Lp(a) concentrations in serum (1330 mgfL and 810 mg/L, respectively), and it was 360 mg/L in the third.
Discussion
Conditions associated with high concentrations of Lp(a) are under intensive investigation.
Well-known hypolipidemic drugs, such as fibric acid derivatives or inhibitors of hydroxymethylglutaryl-CoA reductase (EC 1.1.1.88) did not show any decreasing effect on the genetically determined Lp(a) concentration. Thus, it is of great interest to learn how damage to kidney tissue may influence the otherwise very stable Lp(a) concentration (15) . We found no alterations in renal function in these patients, and values for serum creatinine were within the normal reference interval. The divergent effects of renal damage on serum lipids and Lp(a) concentration suggest that the mechanisms of these disturbances of lipoprotein metabolism may also differ. In two specific types of diffuse chronic glomerulopathy-MCD and membranoproliferative glomerulonephritis-we found apparently contradictory results in the correlations between urinary protein loss and serum Lp(a). The Lp(a) concentrations of MCD patients were within the normal reference interval, no different from controls. In contrast, in the patients with membranoproliferative gbmerulonephritis the Lp(a) values were significantly increased. Possibly, in patients with MCD the selective 
